Home » Authors » Nuala Moran

Articles by Nuala Moran

Sequenom CEO: Companies 'Lost' In Human Gene Biology

May 28, 2003

IP2IPO Invests In King's College In Return For Stake In Spinouts

May 28, 2003

Chiron Plans To Pay £542 Million In Cash To Acquire PowderJect

May 21, 2003

LONDON - Chiron Corp. plans to acquire PowderJect Pharmaceuticals plc in an agreed-to cash offer valuing the vaccines manufacturer at £542 million (US$878 million). (BioWorld International)

MedPharma Postpones IPO As Markets Remain Resistant

May 21, 2003

CAT Cuts Staff As Part Of Plan To Concentrate On Development

May 21, 2003

Chiron Plans To Pay £542 Million In Cash To Acquire PowderJect

May 21, 2003

LONDON - Chiron Corp. plans to acquire PowderJect Pharmaceuticals plc in an agreed-to cash offer valuing the vaccines manufacturer at £542 million (US$878 million). (BioWorld International)

CAT Cuts Staff As Part Of Plan To Concentrate On Development

May 21, 2003

MedPharma Postpones IPO As Markets Remain Resistant

May 21, 2003

Acambis Benefits From U.S. Consolidation Of Contracts

May 14, 2003

UK Industry Riding Out Downturn, Surviving Till Sector Turns Around

May 14, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 18, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 18, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...